Want to see HK:2410 full AI Analyst Report?
Top Page
TYK Medicines, Inc. Class H
(2410)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$3.00
â–¼(-76.80% Downside)
Action:Reiterated
Date:09/12/26
The score is held down primarily by weak financial performance (minimal revenue, persistent large losses, and significant negative operating/free cash flow) and a strongly bearish technical setup (price far below key moving averages with negative MACD and very low RSI/Stochastics). Valuation contributes only modestly because the negative P/E is loss-driven and dividend yield data is not available.
Positive Factors
Narrowing Net Loss
The substantial reduction in net loss indicates some improvement in cost control or operating efficiency compared with the prior year. Although profitability remains distant, a continuing decline in losses could extend financial flexibility and support progress toward a more sustainable business model.
Negative Factors
Pre-Commercial Revenue Base
The absence of meaningful revenue demonstrates that the company has not yet established commercial traction or a recurring funding engine from customers. Without a material revenue base, future progress depends on successful development and eventual commercialization rather than current operating performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing Net Loss
The substantial reduction in net loss indicates some improvement in cost control or operating efficiency compared with the prior year. Although profitability remains distant, a continuing decline in losses could extend financial flexibility and support progress toward a more sustainable business model.
Read all positive factors
TYK Medicines, Inc. Class H (2410) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.02B
Dividend YieldN/A
Average Volume (3M)5.27M
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees173
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding380,065,830
10 Day Avg. Volume8,513,539
30 Day Avg. Volume5,268,848
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)15.38
Price to Sales (P/S)0.00
P/FCF Ratio-17.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)HK$504.00M
TYK Medicines, Inc. Class H Business Overview & Revenue Model
Company Description
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug can...
TYK Medicines, Inc. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 107.00K | 0.00 | 44.24M |
| Gross Profit | 0.00 | -24.37M | 14.00K | -27.66M | 20.04M |
| EBITDA | -199.38M | -289.82M | -346.03M | -346.80M | -292.22M |
| Net Income | -219.05M | -292.01M | -386.95M | -382.43M | -310.99M |
Balance Sheet | |||||
| Total Assets | 529.30M | 780.07M | 915.69M | 573.14M | 558.36M |
| Cash, Cash Equivalents and Short-Term Investments | 158.31M | 367.44M | 435.46M | 192.83M | 243.49M |
| Total Debt | 120.72M | 152.81M | 176.85M | 1.33B | 82.33M |
| Total Liabilities | 1.57B | 449.15M | 443.13M | 1.45B | 1.06B |
| Stockholders Equity | -1.05B | 286.79M | 469.09M | -973.82M | -505.94M |
Cash Flow | |||||
| Free Cash Flow | -154.55M | -255.18M | -381.87M | -278.20M | -308.23M |
| Operating Cash Flow | -136.28M | -215.77M | -308.25M | -200.94M | -220.05M |
| Investing Cash Flow | -120.14M | 35.95M | -135.86M | 73.01M | -158.16M |
| Financing Cash Flow | 114.65M | 126.38M | 632.08M | 224.00M | 351.14M |
TYK Medicines, Inc. Class H Technical Analysis
Negative
12.93
Price Trends
6.54
Negative
7.31
Negative
9.82
Negative
Market Momentum
-0.93
Positive
25.47
Positive
6.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2410, the sentiment is Negative. The current price of 12.93 is above the 20-day moving average (MA) of 5.64, above the 50-day MA of 6.54, and above the 200-day MA of 9.82, indicating a bearish trend. The MACD of -0.93 indicates Positive momentum. The RSI at 25.47 is Positive, neither overbought nor oversold. The STOCH value of 6.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2410.
TYK Medicines, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.85B | 6.29 | 13.26% | 9.52% | -0.47% | -0.40% | |
60 Neutral | HK$2.76B | 13.31 | 4.45% | 0.27% | 7.38% | 7.90% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$4.77B | 7.59 | 47.76% | ― | 286.20% | ― | |
50 Neutral | HK$2.59B | 2.47 | -64.89% | ― | -99.15% | ― | |
48 Neutral | HK$3.23B | -19.27 | -7.65% | ― | 21.23% | 36.89% | |
41 Neutral | HK$1.02B | -3.27 | -77.26% | ― | ― | ― |
* General Sector Average
HK:2410
TYK Medicines, Inc. Class H
2.99
-11.66
-79.61%
HK:9996
Peijia Medical Ltd.
4.77
-2.53
-34.66%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.78
-5.59
-49.16%
HK:1873
Viva Biotech Holdings
1.28
-1.29
-50.19%
HK:2197
Clover Biopharmaceuticals Ltd.
1.91
0.25
15.06%
HK:2633
Jacobson Pharma Corporation Limited
0.95
-0.42
-30.56%
TYK Medicines, Inc. Class H Corporate Events
TYK Medicines CEO Boosts Stake With New H-Share Purchases
Sep 10, 2026
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company by acquiring 635,000 H shares on the open market between September 8 and 10, 2026, for abou...
TYK Medicines CEO Boosts Personal Stake While Upholding Public Float
Sep 8, 2026
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company through open-market share purchases funded by his personal resources. He has indicated that...
TYK Medicines Wins Conditional China Nod for Next‑Generation Lung Cancer Drug
Aug 27, 2026
TYK Medicines, Inc. announced that its self‑developed Asandeutertinib Mesylate Tablets (TY‑9591), a next‑generation, irreversible and highly selective EGFR‑TKI, has received conditional marketing approval from China’s...
TYK Medicines Extends Deadline for Major H-Share Subscription Deal
Aug 20, 2026
TYK Medicines, Inc., a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2410, is building its business around licensing and collaboration deals and the issuance of H shares under general mandates. The company’s...
TYK Medicines Clarifies Board Structure and Committee Roles
Aug 17, 2026
TYK Medicines, Inc., a Hong Kong-listed pharmaceutical and biotechnology company incorporated in the People’s Republic of China, has structured its board with executive, non-executive and independent non-executive directors to support its re...
TYK Medicines Narrows Interim Loss as Other Income Surges Despite Higher R&D Spend
Aug 17, 2026
TYK Medicines, Inc. reported an unaudited total comprehensive loss of RMB26.9 million for the six months ended June 30, 2026, a sharp improvement from a RMB114.1 million loss a year earlier, supported by a strong rise in other income and gains to ...
TYK Medicines reshapes board roles and plans director re-election
Aug 17, 2026
TYK Medicines, Inc. announced the resignation of non-executive director Dr. Jiang Mingyu, who stepped down effective August 17, 2026 to focus on other business endeavors, and confirmed there were no disputes or claims related to his departure. Con...
TYK Medicines Schedules Board Meeting to Approve Interim Results and Consider Dividend
Aug 5, 2026
TYK Medicines, Inc., a PRC-based pharmaceutical company listed in Hong Kong under stock code 2410, operates within the biopharmaceutical and healthcare sector, leveraging mainland China’s research base and Hong Kong’s capital markets. ...
TYK Medicines Launches Legal Challenge Over TY-9591 Agreements
Jul 22, 2026
TYK Medicines has initiated legal proceedings in the People’s Court of Changxing County seeking judicial confirmation that a purported cooperation and distribution agreement with Sichuan Huiyu Pharmaceutical relating to its drug candidate TY...
TYK Medicines Strikes Major TY-9591 Deal With Qilu and Raises RMB400m via H Share Placement
Jul 21, 2026
TYK Medicines has entered into a license, collaboration, supplies and commercialization framework with Qilu to co-develop and manufacture the TY-9591 API and commercialize Kardorisso/TY-9591 in China. The deal includes an upfront cash payment of R...
TYK Medicines Wins Shareholder Approval for New Share Issue Mandate
Jul 15, 2026
TYK Medicines, Inc., a Hong Kong-listed pharmaceutical company based in Shanghai, convened its first extraordinary general meeting of 2026 with full board attendance and compliance with PRC Company Law and its Articles of Association. Shareholders...
TYK Medicines calls July EGM to seek mandate for new share issuance
Jun 29, 2026
TYK Medicines, Inc. has called its first extraordinary general meeting of 2026 for July 15 in Shanghai, where shareholders will vote on a special resolution to grant the board an issue mandate to issue new shares. The meeting will be conducted by ...
TYK Medicines Sets Share Register Closure Ahead of Extraordinary General Meeting
Jun 24, 2026
TYK Medicines, Inc., a Hong Kong–listed Chinese pharmaceutical company, has announced administrative arrangements for shareholders ahead of an upcoming extraordinary general meeting. The move underscores the company’s adherence to Hong...
TYK Medicines shareholders back key AGM resolutions but reject share issue mandate
Jun 23, 2026
TYK Medicines, Inc. reported the results of its 2025 annual general meeting held in Shanghai on June 23, 2026, where all directors attended in person or electronically and procedures were confirmed compliant with PRC company law. Shareholders appr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.